文献类型： 外文期刊

作者： Liu, Lei ⁴ ; Wu, Wenbin ⁶ ; Zhu, Guangze ² ; Liu, Liming ⁵ ; Guan, Guofang ³ ; Li, Xiao ¹ ; Jin, Ningyi ⁶ ; Chi, Baorong ⁴ ;

作者机构： 1.Minist Educ, Key Lab Pathobiol, Changchun 130021, Peoples R China

2.Changchun Univ Chinese Med, Affiliated Hosp, Clin Lab, Changchun 130021, Peoples R China

3.Jilin Univ, Hosp 2, Changchun 130001, Peoples R China

4.Jilin Univ, Hosp 1, Dept Gastroenterol, Changchun 130021, Peoples R China

5.Jilin Acad Agr Sci arid Technol, Jilin 132101, Peoples R China

6.Acad Mil Med Sci, Genet Engn Lab PLA, Changchun 130122, Peoples R China

关键词： antitumor;apoptin;apoptosis;conditional replication-competent adenovirus;gastric carcinoma

期刊名称：INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE （ 影响因子：4.101； 五年影响因子：4.084 ）

ISSN： 1107-3756

年卷期： 2012 年 30 卷 4 期

页码：

收录情况： SCI

摘要： The efficacy and specificity of treatment are the major challenges for cancer gene therapy. Oncolytic virotherapy is an attractive drug delivery platform of cancer gene therapy. Previous studies have determined that apoptin is a p53-independent, Bcl-2-insensitive apoptotic protein that has the ability to induce apoptosis specifically in tumor cells. In this study, we show that the administration of a dual cancer-specific oncolytic adenovirus construct, Ad-hTERT-Ela-apoptin [in which the adenovirus early region la (Ela) gene is driven by the cancer-specific promoter of human telomerase reverse transcriptase (hTERT) and that expresses apoptin simultaneously], suppresses tumor growth in gastric carcinoma cells in vitro and reduces the tumor burden in vivo in xenografted nude mice. The observation that infection with the Ad-hTERT-Ela-apoptin construct significantly inhibited the growth of gastric cancer cells and protected normal human gastric epithelium from growth inhibition confirmed the induction of cancer cell-selective adenovirus replication, growth inhibition and apoptosis by this therapeutic approach. In vivo assays were performed using BALB/c nude mice that had established primary tumors. Subcutaneous primary tumor volume was reduced not only in the intratumoral injection group but also in the systemic delivery mice following treatment with Ad-hTERT-Ela-apoptin. Furthermore, treatment of primary models with Ad-hTERT-Ela-apoptin increased the mouse survival time. These data reinforce previous research and highlight the potential therapeutic application of Ad-hTERT-Ela-apoptin for the treatment of neoplastic diseases in clinical trials.